RP101 improves the efficacy of gemcitabine in treating pancreatic carcinoma.

Sub-category: Pancreatic Cancer  
Category: Gastrointestinal (Noncolorectal) Cancer  
Meeting: 2006 ASCO Annual Meeting

Abstract No: 14075  
Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14075

Author(s): M. Haenel, D. Quietzsch, V. Heinemann, S. Boeck, R. M. Schmid, A. Liebert, R. Fahrig

Abstract:  
**Background:** (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU, RP101), was initially tested in a phase 1 pilot study in pancreatic cancer. Patients (n=13) received gemcitabine (1000 mg/m²), cisplatin (50 mg/m²) and RP101 (500 mg/day). The median survival was 447 days and the TTP was 280 days. Ten of the 13 pts lived longer than one year, 4 nearly two years. Based on these promising results a phase 2 study was initiated to explore varying doses of RP101 used with a fixed dose of GEM.  
**Methods:** Pts with advanced pancreatic adenocarcinoma were eligible for treatment in this single arm study. 22 pts (16 stage IV and 5 stage III) received GEM 1000 mg/m² on days 1, 8 and 15 of a 28-day schedule. RP101 treatment, at doses of 500, 625, 750, 875 or 1000 mg/day, was on the same day and for three days after chemotherapy. The mean age was 60 years and 73% of pts were males.  
**Results:** The results are based on interim data from an ongoing study and patients at the 2 highest dose groups are still being treated. All RP101 dose groups were combined for analyses, which included all enrolled pts. The data on the 6-month survival status show that 41% are alive; 23% dead; and 36% followed less than 6 months. The median survival (95% CI) is 7.1 months (5.9, not calculated) and 14/22 pts (64%) are still alive. The 6 month survival rate (95% CI) is 0.69 (0.52, 0.85). This compares very favorably with a large recent randomized trial in which pts who received GEM alone had a median survival (95% CI) of 5.9 months (5.1-6.7). PFS and TTP continue to be assessed in this ongoing trial. There appears to be a dose dependent increase in peak GEM levels as a function of the dose of RP101. To date, adverse events are consistent with those observed with GEM or the underlying disease.  
**Conclusion:** RP101 may improve treatment of advanced pancreatic cancer when used with gemcitabine. Updated data on survival, PFS, and safety will be presented based on available data.

Other Abstracts in this Sub-Category

1. **In vivo platform for translational drug development and biomarker discovery in pancreatic cancer.**  
   Meeting: 2006 ASCO Annual Meeting  
   Abstract No: 4000  
   First Author: M. Hidalgo  
   Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer

2. **Tissue factor, angiogenesis and thrombosis in pancreatic cancer.**  
   Meeting: 2006 ASCO Annual Meeting  
   Abstract No: 4001  
   First Author: A. A. Khorana  
   Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer

3. **GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer.**  
   Meeting: 2006 ASCO Annual Meeting  
   Abstract No: 4002  
   First Author: H. Safran  
   Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer  
   More...

Abstracts by M. Haenel

1. **A phase II pilot trial with RP101 in advanced pancreatic carcinoma.**  
   Meeting: 2006 ASCO Annual Meeting  
   Abstract No: 14000  
   First Author: R. Fahrig  
   Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer

2. **RP101 improves the efficacy of gemcitabine in treating pancreatic carcinoma.**  
   Meeting: 2006 ASCO Annual Meeting  
   Abstract No: 14075  
   First Author: M. Haenel  
   Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer

3. **Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma - follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)**  
   Meeting: 2005 ASCO Annual Meeting  
   Abstract No: 6528  
   First Author: M. H. Dreyling
1. **Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies.**

   Intensive Care Med, United States
   Vol 28, No 9 (Sep, 2002): pp. 1294-300
   PMID: 12209280 [PubMed - in process]

More...